FDA Approves New Treatment for Alkaptonuria
Adults with this rare genetic disorder now have access to a newly approved medication to help manage their condition.
Updated on Oct. 21, 2026 in Diseases — General
Live Poll
Do you trust that the healthcare system adequately prioritizes early diagnosis for rare inherited diseases?
The New England Journal of Medicine recently highlighted the rare inherited disorder alkaptonuria, which causes pigment to accumulate in connective tissues. This condition, which can lead to severe joint stiffness and arthritis, is now being addressed by the recently FDA-approved drug Harliku (nitisinone).
Why it matters
Alkaptonuria results from a genetic inability to break down certain amino acids, leading to a buildup of homogentisic acid that damages joints over time. The approval of new treatment options marks a shift in how clinicians manage the long-term progression of this rare disease.
Clinical trial data shows that nitisinone treatment results in an 88% reduction in urine homogentisic acid after one year and 91% after three years compared to baseline levels. These findings build on earlier NIH trials that followed 40 patients over a three-year period.
The players
FDA
The United States federal agency responsible for evaluating the safety and efficacy of medical treatments.
NIH
The primary agency of the United States government responsible for biomedical and public health research.
Archibald Garrod
A physician who pioneered the study of inborn errors of metabolism in the 1900s.
The details
Alkaptonuria occurs when individuals inherit faulty copies of the HGD gene from both parents, preventing the body from producing the enzyme needed to break down phenylalanine and tyrosine. This causes homogentisic acid to build up and turn black upon air exposure, eventually depositing a blue-black pigment known as ochronosis in tissues. The drug Harliku (nitisinone) works upstream in this chemical pathway to reduce the production of the acid before it can accumulate.
Timeline
1900s: Archibald Garrod identified alkaptonuria as an inborn error.
2005-2009: NIH trial followed 40 patients for three years.
2020: European regulators recommended a nitisinone product.
June 2025: FDA approved nitisinone for adult alkaptonuria patients.
October 14, 2026: NEJM published an image report on alkaptonuria.
Health Landscape
The clinical approach to alkaptonuria has evolved from early identification of its metabolic roots by researchers like Archibald Garrod to targeted pharmacological intervention. Recent regulatory approvals follow decades of trial data aiming to mitigate the impact of ochronosis on connective tissues.
Alkaptonuria is rare, affecting roughly 1 in 250,000 to 1 million people in the United States, but patients experiencing unusual joint stiffness or visible pigmentation should consult a physician. Discussing genetic history and specialized metabolic screenings with a doctor is the appropriate next step for those with concerns.
The takeaway
Alkaptonuria is an inherited disorder that requires careful metabolic management to prevent long-term joint damage from pigment buildup. If you notice persistent joint pain or unusual discoloration, speak with your physician about whether genetic or metabolic testing is appropriate.
Further reading
For more on managing systemic health conditions, visit our Diseases — General section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you trust that the healthcare system adequately prioritizes early diagnosis for rare inherited diseases?
